In addition, polyps demonstrate low levels of Activin A whereas patients with CRSsNP demonstrate high levels of both TGF-β1 and Activin A. These studies indicate that ALK activation, through TGF-β1 and Activin A, is low in nasal polyps and possibly contributing to disease progression. The gene discussed is ALK; the disease is nasal cavity polyp.